FDA Clears Tasso+ Lancet for Virtually Painless Blood Collection

Tasso has earned U.S. Food and Drug Administration (FDA) clearance for its Tasso+ lancet device for simple and virtually painless blood collection.
 
The single-use, patient-centric blood collection device is the first to earn Class I clearance as part of the new reclassification process for lancets. Tasso+ will we widely available across the U.S. in Q4 2022.
 
“With continued industry interest in decentralized clinical trials and diverse testing applications, demand for our high-quality, virtually painless, convenient blood collection solutions is at an all-time high,” Ben Casavant, Ph.D., CEO and co-founder of Tasso told the press. “This FDA Class II medical device clearance will help improve patient care by relieving traditional phlebotomy-related bottlenecks and enabling more individuals to get the tests they need at the time they are needed. We are excited to unlock a new wave of large commercial opportunities for the company and to lead the industry into the future of remote testing.”